NCT01839240 - Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 6, 2012

Primary Completion Date

August 16, 2019

Study Completion Date

August 16, 2019

Conditions

Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia

Interventions

DRUG

azacitidine

Given IV or SC

DRUG

cytarabine

Given IV

DRUG

mitoxantrone hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER